Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

UK biotech Epsilogen has acquired US-based antibody developer TigaTx in a deal that collates work from the two companies’ ...

In vitro, omalizumab and human IgE form several immune complexes that vary in size as the 2 components' molar ratios are changed. [29] The largest complex, a stable cyclical hexameric structure ...

A new anti-HER2 IgE antibody potentially offers new therapy options for treatment-resistant breast and ovarian cancers.

U.K.-based Epsilogen has bought Boston biotech TigaTx with the aim of creating “the world’s leading pan-isotype cancer ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.

However, this treatment is not always effective in some patients. Now scientists have investigated a different antibody type, IgE, which activates the patient's immune system in different ways to IgG.

The combined company will clinically advance Epsilogen's MOv18 IgE antibody in ovarian cancer and TigaTx's anti-EGFR IgA antibody.

serum total immunoglobulin E levels, skin prick-test and patch-test results. The present study has show that the disease is more frequent in females and during the third decade of life ...

IgM, IgD, IgA, IgG, IgG1, 2, 3, and 4, and total IgE were measured. Results ... Conclusions: In experienced ultra-endurance runners, alterations in immunoglobulin concentrations after a race suggest ...

Research has shed light on how a new type of antibody treatment reactivates patients’ immune cells to fight ovarian cancer.